Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Teosyal PureSense Global Action is a sterile, transparent, cross-linked hyaluronic acid (HA) gel of non-animal origin, containing 0.3% lidocaine hydrochloride for its anesthetic properties. Developed by Teoxane Laboratories, it is part of the Teosyal PureSense range of dermal fillers. While primarily indicated for the treatment of moderate wrinkles, nasolabial folds, and cutaneous depressions, it is being evaluated in clinical research (such as trials at Altinbas University) for the reconstruction of interdental papilla loss, commonly known as "black triangles." The hyaluronic acid component acts as a mechanical volumizing agent by binding water and providing structural support to the gingival tissue, while the lidocaine component serves as a local anesthetic to minimize pain during the injection procedure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Teosyal PureSense Global Action.